Every 10-Q that Dogwood Therapeutics, Inc. (DWTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow DWTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DWTX filings page.
Dogwood Therapeutics, Inc. reported no revenue for the three and six months ended June 30, 2026 and remains a pre-revenue, development-stage biopharmaceutical company focused on cancer-related pain and chemotherapy-induced neuropathy.
The company posted a net loss of $11.5 million for the quarter and $16.5 million for the first half of 2026, driven by $3.2 million in research and development, $1.6 million in general and administrative expenses, and a $9.2 million IPR&D impairment in the quarter. A net non-cash IPR&D impairment charge of $6.7 million was recognized after a related deferred tax benefit.
Cash and cash equivalents increased to $9.6 million as of June 30, 2026, helped by $11.4 million of net proceeds from a January 2026 equity offering, but operating activities used $8.2 million of cash in the first half. Accumulated deficit reached $124.6 million and management disclosed substantial doubt about the company’s ability to continue as a going concern beyond the fourth quarter of 2026 without additional financing.
Dogwood Therapeutics, Inc. filed its Form 10-Q reporting first-quarter 2026 results as a pre-revenue, development-stage biopharmaceutical company focused on cancer pain and neuropathy. The company posted a net loss of $4,986,614 for the three months ended March 31, 2026, narrowing from $10,924,952 a year earlier, as total operating expenses were $5,076,366.
Cash and cash equivalents increased to $13,227,839 at March 31, 2026 from $6,524,744 at year-end 2025, helped by net proceeds of about $11.4M from a January 2026 equity and warrant financing. The accumulated deficit reached $113,062,930, and management states that existing cash will not fund operations for at least 12 months, indicating substantial doubt about the company’s ability to continue as a going concern without additional financing.
Dogwood Therapeutics (Nasdaq: DWTX) filed its Q3 2025 10‑Q, reporting a net loss of $15.7 million as R&D climbed, driven by $12.0 million of acquired in‑process R&D tied to a new SP16 license. For the nine months, net loss was $30.5 million, including a $6.1 million loss recognized on a related‑party debt conversion.
Cash was $10,126,710, with net cash used in operating activities of $11,981,464 for the nine months. Management states there is substantial doubt about the company’s ability to continue as a going concern beyond the first quarter of 2026 without additional financing.
During March 2025, the company raised approximately $4.25 million net in a registered direct offering and exchanged $19.9 million of related‑party loans and interest into Series A‑1 Non‑Voting Convertible Preferred Stock. On September 29, 2025, Dogwood licensed SP16 from Serpin, issuing equity valued at $12,030,667. As of November 5, 2025, 2,293,162 common shares were outstanding.